ArticleLupus science & medicine2020
Similar progression of carotid intima-media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher prednisolone usage in patients.
Article in Lupus science & medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 32 citations in OpenAlex.
- Prevalence of Carotid Atherosclerosis in Adult Populations in Europe and North America (USA, Canada): A Systematic Review of Population-Based Studies (2015-2025).Diagnostics (Basel, Switzerland) · 2026Review
- Atherosclerotic Plaque Progression and Incident Cardiovascular Events in a 10-Year Prospective Study of Patients With Systemic Lupus Erythematosus: The Impact of Persistent Cardiovascular Risk Factor Target Attainment and Sustained DORIS Remission.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- Lupus nephritis as an independent risk factor for carotid atherosclerosis in patients with systemic lupus erythematosus.Clinical rheumatology · 2025Article
- Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics.Signal transduction and targeted therapy · 2025Review
- Exploring the Association Between Systemic Lupus Erythematosus and High-Density Lipoproteins: A Systematic Review and Meta-Analysis.ACR open rheumatology · 2024Review
- Frailty is independently associated with subclinical cardiovascular disease in patients with systemic lupus erythematosus.RMD open · 2024Article
- Association between metabolic syndrome and lupus nephritis activity.Journal of medical biochemistry · 2024Article
- The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus.Rheumatology (Oxford, England) · 2024Article
- Proposal of a novel cardiovascular risk prediction score in lupus nephritis.Frontiers in immunology · 2024Article
- Extent of vascular plaque predicts future cardiovascular events in patients with systemic lupus erythematosus.Rheumatology (Oxford, England) · 2022Article
- The effects of glucocorticoid treatment on cardiovascular system in patients with systemic lupus erythematosus.Archives of rheumatology · 2022Article
- Obesity, Diabetes, and Cardiovascular Risk Burden in Systemic Lupus Erythematosus: Current Approaches and Knowledge Gaps-A Rapid Scoping Review.International journal of environmental research and public health · 2022Article
- Study of common hypertriglyceridaemia genetic variants and subclinical atherosclerosis in a group of women with SLE and a control group.Lupus science & medicine · 2022Article
- Review
- QRISK3-based analysis of cardiovascular risk factors in patients with long-term but well-controlled systemic lupus erythematosus.American journal of translational research · 2022Article
- The Causal Relationship Between Blood Lipids and Systemic Lupus Erythematosus Risk: A Bidirectional Two-Sample Mendelian Randomization Study.Frontiers in genetics · 2022Article
- Risk factors for changes in carotid intima media thickness and plaque over 5 years in women with systemic lupus erythematosus.Lupus science & medicine · 2021Article
- Cardiovascular disease in systemic lupus erythematosus.Rheumatology and immunology research · 2021Review
- Disease activity index is associated with subclinical atherosclerosis in childhood-onset systemic lupus erythematosus.Pediatric rheumatology online journal · 2021Article
- The latest in systemic lupus erythematosus-accelerated atherosclerosis: related mechanisms inform assessment and therapy.Current opinion in rheumatology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare progression of subclinical atherosclerosis and factors promoting it in patients with SLE and controls. Methods: Consecutive patients with SLE and age-matched, sex-matched population controls from the SLEVIC cohort were assessed at inclusion and after 7 years with standardised data collection and carotid ultrasound. Effect of risk factors on carotid intima-media thickness (cIMT) progression was examined with adjusted linear mixed models. Results: A total of 77 patients and 74 controls, 68% and 61% of the original cohort, completed follow-up. The patients were (mean) 47 years old, 90% were women, and controls were 51 years old, 92% women. Patients had disease duration of (mean) 11 years, mild disease activity and low severity at both assessments. Baseline cIMT did not differ between the groups. An average absolute cIMT progression was 0.009 mm/year in patients and 0.011 mm/year in controls, intergroup difference p=0.9.Of factors at inclusion, dyslipidaemia, lower levels of high-density lipoprotein (HDL) and carotid plaque in patients and controls, and higher systolic blood pressure, total cholesterol:HDL and LDL:HDL ratios and triglycerides in patients were associated with cIMT progression. Of factors at follow-up, hypertension and blood lipids in patients and HDL in controls were significantly associated with cIMT progression. History of lupus nephritis and a higher average dose of prednisolone used since diagnosis were associated with cIMT progression in patients. Associations of risk factors with cIMT progression were stronger in presence of plaques. Conclusion: We observed a statistically comparable progression of cIMT in patients with mild SLE and controls over 7 years, which implies that progression of subclinical atherosclerosis in some patients with SLE could follow that of the general population. Traditional cardiovascular (CV) risk factors, history of lupus nephritis and higher use of corticosteroids promote cIMT progression in SLE. Detection of carotid plaque may add to CV risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.